Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
52°
Mostly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
130.99
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, May 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
...
29
30
31
32
33
34
35
36
37
...
66
67
Next >
7 Penny Stocks That Actually Have a Buy Rating
September 19, 2022
Penny stocks are always a risky proposition. However, investors can still find penny stocks with buy ratings right now.
Via
InvestorPlace
Why Hedge Funds Are Piling In These 2 High Yielding Stocks
September 18, 2022
As we move further into the second half of the year, many investors will find themselves repositioning to better allocate their investments to mitigate risks. Some investors prefer to take positions in...
Via
Benzinga
7 Undervalued Stock Picks to Beat the September Market Slump
September 16, 2022
While seeing a wave of red ink isn’t fun during the middle of a steep selloff, it also opens opportunities for undervalued stock picks.
Via
InvestorPlace
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
Immutep Issues Development Update For Its Lead Cancer Candidate
September 14, 2022
Via
Benzinga
Analyst Ratings for Merck & Co
September 12, 2022
Analysts have provided the following ratings for Merck & Co (NYSE:MRK) within the last quarter:
Via
Benzinga
What Are Whales Doing With Merck & Co
September 14, 2022
Someone with a lot of money to spend has taken a bullish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
September 14, 2022
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low...
Via
Benzinga
Evercore ISI Group Boosts PT On This Stock By Around 400%, Plus This Analyst Predicts $100 For Merck
September 14, 2022
Berenberg raised the price target for Merck & Co., Inc. (NYSE: MRK) from $95 to $100. Merck shares rose 0.7% to $86.22 in pre-market trading.
Via
Benzinga
Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
September 13, 2022
Via
Benzinga
Merck Secures Canadian Regulatory Nod For KEYTRUDA In Skin Cancer After Resection
September 13, 2022
Health Canada has granted approval for Merck’s (NYSE: MRK) KEYTRUDA (pembrolizumab) for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma...
Via
Benzinga
After FDA Regulatory Setback, Penny Stock ObsEva Cuts 70% Of Its Staff
September 13, 2022
Via
Benzinga
This Is What Whales Are Betting On Merck & Co
September 12, 2022
A whale with a lot of money to spend has taken a noticeably bearish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 17 strange trades.
Via
Benzinga
BP To $47? Plus UBS Sees $2,260 For This Stock
September 12, 2022
Piper Sandler boosted the price target for BP p.l.c. (NYSE: BP) from $44 to $47. BP shares rose 2.1% to trade at $32.34 on Monday.
Via
Benzinga
Five-Year Data For Merck's Keytruda Plus Chemo Shows Sustained Survival Benefit In Lung Cancer Patients
September 12, 2022
Via
Benzinga
Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer
September 12, 2022
Via
Benzinga
Merck Gambled With Keytruda In 2011 — How That Jump Is Still Paying Off Today
September 11, 2022
In two new studies, Keytruda doubled patients' survival rate after five years.
Via
Investor's Business Daily
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
September 09, 2022
Via
Benzinga
AstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer
September 09, 2022
Via
Benzinga
Top Financial Stories Thursday, September 1: Netflix Weighs Charging High Sum For Ads, Self Harm posts Grow On Twitter, California Fast-Food Bill Faces Industry Backlash...
September 01, 2022
Wall Street Journal
Via
Benzinga
Novartis Appoints Merck Executive As Research Head
September 01, 2022
Via
Benzinga
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
August 30, 2022
Via
Benzinga
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
August 29, 2022
These names are benefitting from M&A, clinical data and promising regulatory actions.
Via
Investor's Business Daily
Bristol Myers-JNJ Partnered Secondary Stroke Drug Misses Endpoint, But Companies See Enough Potential For Phase 3 Trials
August 29, 2022
Via
Benzinga
Merck's Rumored $40 Billion Seagen Takeover Hits A Snag On Price
August 26, 2022
The companies could still reach a deal, but have failed to see eye to eye on price.
Via
Investor's Business Daily
Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26
August 26, 2022
CNBC The Aviation Sector Is Slammed By Sky-High Rents
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
August 26, 2022
We're starting off the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday!
Via
InvestorPlace
Merck's Buyout Of Seagen Hits Speed Braker Over Price Agreement: Report
August 26, 2022
Via
Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
August 25, 2022
Via
Benzinga
Back-To-Back Three Japanese Approvals For AstraZeneca's Rare Disease Treatments
August 25, 2022
Via
Benzinga
< Previous
1
2
...
29
30
31
32
33
34
35
36
37
...
66
67
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.